Published in Annu Rev Med on January 01, 1983
Value of needle aspiration in bacteriologic diagnosis of cellulitis in adults. J Clin Microbiol (1988) 1.12
Chitin modulates innate immune responses of keratinocytes. PLoS One (2011) 0.93
A review of current strategies to reduce intraoperative bacterial contamination of surgical wounds. GMS Krankenhhyg Interdiszip (2007) 0.80
Diagnosis of cellulitis in the immunocompromised host. Can J Infect Dis (1990) 0.75
Fever and pulmonary infiltrates in a patient with a renal transplant. West J Med (1984) 0.75
Diagnosis of cellulitis in patients infected with the human immunodeficiency virus. Can J Infect Dis (1994) 0.75
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother (1985) 11.34
Infection in organ-transplant recipients. N Engl J Med (1998) 6.49
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother (1985) 6.44
Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother (1986) 6.20
Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob Agents Chemother (1989) 5.09
Pasteurella multocida infections. Report of 34 cases and review of the literature. Medicine (Baltimore) (1984) 5.04
Fluoroquinolone antimicrobial agents. N Engl J Med (1991) 4.65
Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob Agents Chemother (1988) 4.47
Mechanisms of action of and resistance to ciprofloxacin. Am J Med (1987) 4.46
Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis. J Immunol (1981) 3.71
A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus. J Bacteriol (1991) 3.70
Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med (1981) 3.63
Cryptosporidiosis in immunocompetent patients. N Engl J Med (1985) 3.62
Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth. Antimicrob Agents Chemother (1982) 3.15
Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation. Antimicrob Agents Chemother (1989) 2.99
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Vancomycin-resistant gram-positive bacteria isolated from human sources. J Clin Microbiol (1988) 2.71
Clinical, microbiologic and therapeutic aspects of purulent pericarditis. Am J Med (1975) 2.46
Infective endocarditis--1973. Prog Cardiovasc Dis (1974) 2.42
Efficacy of single-dose and conventional amoxicillin therapy in urinary-tract infection localized by the antibody-coated bacteria technic. N Engl J Med (1978) 2.33
Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation (1981) 2.22
Hepatic abscess: changes in clinical, bacteriologic and therapeutic aspects. Am J Med (1974) 2.21
Molecular epidemiology of adhesin and hemolysin virulence factors among uropathogenic Escherichia coli. Infect Immun (1989) 2.12
Drug therapy. Serum bactericidal activity as a monitor of antibiotic therapy. N Engl J Med (1985) 2.07
Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus. Antimicrob Agents Chemother (1993) 2.04
The release of four mediators of immediate hypersensitivity from human leukemic basophils. J Immunol (1975) 1.92
Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med (1990) 1.92
Automatic differentiation of melanoma from melanocytic nevi with multispectral digital dermoscopy: a feasibility study. J Am Acad Dermatol (2001) 1.91
Emerging resistance to fluoroquinolones in staphylococci: an alert. Ann Intern Med (1991) 1.88
Nonepidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus. Plast Reconstr Surg (1981) 1.86
Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med (1979) 1.83
Narrower margins for clinical stage I malignant melanoma. N Engl J Med (1982) 1.82
Primary melanoma of the skin: recognition and management. J Am Acad Dermatol (1980) 1.82
Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med (1981) 1.77
An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol (1998) 1.76
BK virus in solid organ transplant recipients: an emerging syndrome. Transplantation (2001) 1.75
Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol (2001) 1.75
Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg (1982) 1.72
Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer (1997) 1.71
Imaging focal sites of bacterial infection in rats with indium-111-labeled chemotactic peptide analogs. J Nucl Med (1991) 1.65
Does biopsy type influence survival in clinical stage I cutaneous melanoma? J Am Acad Dermatol (1985) 1.64
Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography. Antimicrob Agents Chemother (1993) 1.55
Genetics and regulation of outer membrane protein expression by quinolone resistance loci nfxB, nfxC, and cfxB. Antimicrob Agents Chemother (1992) 1.54
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54
Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy. Ann Intern Med (1986) 1.48
The natural break points for primary-tumor thickness in clinical Stage I melanoma. N Engl J Med (1981) 1.45
Adverse reactions to duck embryo rabies vaccine. Range and incidence. Ann Intern Med (1973) 1.44
An association between cryptosporidium and giardia in stool. N Engl J Med (1984) 1.43
Single-dose amoxicillin therapy for urinary tract infection. Multicenter trial using antibody-coated bacteria localization technique. JAMA (1980) 1.43
Acral lentiginous melanoma (including in situ melanoma) arising in association with naevocellular naevi. Melanoma Res (1996) 1.42
Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J (2000) 1.41
Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation (1977) 1.40
The therapeutic prescription for the transplant patient. Transpl Infect Dis (2002) 1.39
A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease. Ann Surg (1981) 1.38
In search of the hot appendix--a clinician's view of inflammation imaging. J Nucl Med (1990) 1.38
Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg (1982) 1.38
Sun exposure habits in patients with cutaneous melanoma: a case control study. J Dermatol Surg Oncol (1983) 1.37
Neurologic complications of bacterial endocarditis. Medicine (Baltimore) (1978) 1.36
Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology (1995) 1.35
Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg (1981) 1.34
A prognostic model for clinical stage I melanoma of the lower extremity. Location on foot as independent risk factor for recurrent disease. Surgery (1981) 1.33
Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer (1995) 1.33
Cytomegalovirus antigenemia: clinical correlations in transplant recipients and in persons with AIDS. J Clin Microbiol (1993) 1.33
Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A (1996) 1.31
Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA (1987) 1.30
Antagonism of the B subunit of DNA gyrase eliminates plasmids pBR322 and pMG110 from Escherichia coli. J Bacteriol (1982) 1.29
Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation (1985) 1.29
Mode of action of the new quinolones: new data. Eur J Clin Microbiol Infect Dis (1991) 1.27
Central nervous system infection in the chronically immunosuppressed. Medicine (Baltimore) (1982) 1.27
Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer (1993) 1.27
Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1993) 1.27
Production of a low molecular weight eosinophil polymorphonuclear leukocyte chemotactic factor by anaplastic squamous cell carcinomas of human lung. J Clin Invest (1978) 1.26
Ethnicity and physician-older patient communication about alternative therapies. J Altern Complement Med (2001) 1.25
Infection in the renal transplant recipient. Am J Med (1981) 1.25
A case of human rabies in Kansas: epidemiologic, clinical, and laboratory considerations. J Infect Dis (1970) 1.24
Antidepressant prescribing to Hispanic and non-Hispanic white patients in primary care. Ann Pharmacother (2001) 1.24
A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models. Ann Surg (1982) 1.24
The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol (1987) 1.23
Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med (1983) 1.23
Bacterial resistance to the quinolone antimicrobial agents. Am J Med (1989) 1.23
Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation (1996) 1.22
Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J Immunol (1982) 1.21
Single-dose therapy with trimethoprim-sulfamethoxazole for urinary tract infection in women. Rev Infect Dis (1982) 1.21
Confocal scanning laser microscopy of benign and malignant melanocytic skin lesions in vivo. J Am Acad Dermatol (2001) 1.20
Cell migration and actin organization in cultured human primary, recurrent cutaneous and metastatic melanoma. Time-lapse and image analysis. Am J Pathol (1991) 1.20
Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection. Transplantation (1984) 1.20
Sunlight and skin cancer. N Engl J Med (1985) 1.20
Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. N Engl J Med (1983) 1.18
Effects of antithymocyte globulin on cytomegalovirus infection in renal transplant recipients. Transplantation (1981) 1.18
Hepatitis C virus and organ transplantation. Transplantation (1996) 1.17
Accumulation of immunoglobulin G at focal sites of inflammation. Eur J Nucl Med (1992) 1.17
Basic skin cancer triage for teaching melanoma detection. J Am Acad Dermatol (1996) 1.17
Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation (1992) 1.16
Mode of action of the quinolone antimicrobial agents. Rev Infect Dis (1988) 1.16
Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer (1999) 1.15
Rapid method for screening large numbers of Escherichia coli colonies for production of plasmid-mediated beta-lactamases. Antimicrob Agents Chemother (1983) 1.15
Defective human mononuclear leukocyte chemotaxis as an index of host resistance to malignant melanoma. Clin Immunol Immunopathol (1976) 1.15